Health
Molnupiravir (MK-4482/EIDD-2801) Antiviral — Precision Vaccinations – PrecisionVaccinations
Molnupiravir (MK-4482/EIDD-2801) antiviral is indicated to mitigate SARS-CoV-2 infection and block transmission, hence preventing COVID-19 disease.
Molnupiravir (MK-4482/EIDD-2801) Antiviral Description
Molnupiravir (MK-4482/EIDD-2801) is an oral antiviral drug that was originally developed for the treatment of influenza. MK-4482/EIDD-2801 consists of the nucleoside analogue N4-hydroxycytidine (NHC). Molnupiravir has been evaluated against coronaviruses (CoVs) including SARS-1, MERS-CoV, and SARS-CoV-2.
The drug was originally developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE)….
-
General15 hours agoStar Wars’ fascist dystopia has never felt closer than in new season of Andor
-
General18 hours agoCoalition to chart path forward as family feud cooled
-
Noosa News18 hours agoInterest rates: Why we will keep paying the same repayments
-
Noosa News14 hours agoQueensland Premier David Crisafulli keeps clear of Coalition chaos in Canberra